Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations i… Read more
Marinus Pharmaceuticals Inc (MRNS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.291x
Based on the latest financial reports, Marinus Pharmaceuticals Inc (MRNS) has a cash flow conversion efficiency ratio of 0.291x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.45 Million) by net assets ($-66.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Marinus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Marinus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Marinus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marinus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Celik Halat ve Tel Sanayi AS
IS:CELHA
|
-0.079x |
|
LPS Brasil - Consultoria de Imóveis S.A
SA:LPSB3
|
0.085x |
|
HEALTH NET
F:HNT
|
N/A |
|
Titania Holding AB Series B
ST:TITA-B
|
-0.051x |
|
Metallic Minerals Corp
OTCQB:MMNGF
|
-0.327x |
|
Alto Metals Ltd
AU:AME
|
-0.025x |
|
Cayenne Entertainment Technology Co. Ltd.
TWO:4946
|
-0.768x |
|
Solid State System Co. Ltd.
TWO:3259
|
-0.074x |
Annual Cash Flow Conversion Efficiency for Marinus Pharmaceuticals Inc (2012–2023)
The table below shows the annual cash flow conversion efficiency of Marinus Pharmaceuticals Inc from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $16.77 Million | $-118.00 Million | -7.039x | -623.27% |
| 2022-12-31 | $116.00 Million | $-112.89 Million | -0.973x | +6.18% |
| 2021-12-31 | $53.49 Million | $-55.48 Million | -1.037x | -133.63% |
| 2020-12-31 | $137.20 Million | $-60.91 Million | -0.444x | +19.88% |
| 2019-12-31 | $87.77 Million | $-48.63 Million | -0.554x | -35.98% |
| 2018-12-31 | $68.33 Million | $-27.84 Million | -0.407x | -25.63% |
| 2017-12-31 | $58.01 Million | $-18.82 Million | -0.324x | +71.87% |
| 2016-12-31 | $21.48 Million | $-24.77 Million | -1.153x | -168.81% |
| 2015-12-31 | $46.92 Million | $-20.13 Million | -0.429x | -105.55% |
| 2014-12-31 | $41.15 Million | $-8.59 Million | -0.209x | +70.22% |
| 2013-12-31 | $9.46 Million | $-6.63 Million | -0.701x | -138.58% |
| 2012-12-31 | $4.18 Million | $-1.23 Million | -0.294x | -- |